Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
详细描述
Peritoneal carcinomatosis is a dooming finding with no hope for cure and a steadily decrease in quality of life. Cytoreductive surgery with intraperitoneal chemotherapy (CRS HIPEC) offers a small but proven chance for cure. The implementation of a CRS HIPEC and PIPAC programme in a Swiss tertiary care hospital is evaluated.
When a patient is deemed non resectable, pressurized intraperitoneal aerosol chemotherapy (PIPAC) administered laparoscopically may confer effective palliation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and Women >18 years
- •Tumour board decision for CRS and intraoperative chemotherapy
排除标准
- •Missing Tumour board decision for CRS and intraoperative chemotherapy
- •Pregnancy
- •Age <18 years
结局指标
主要结局
Overall Survival
时间窗: 5 years
All cause mortality since diagnosis/Intervention (in months)
Postoperative surgical complications
时间窗: 90 days
Reporting and grading of postoperative surgical complications (according to Dindo)
Disease-free survival
时间窗: 5 years
Time to recurrence measured since diagnosis/Intervention (in months)
Rehospitalisation
时间窗: 90 days
Rehospitalisation: (yes/no), time frame, cause of rehospitalisation
次要结局
- Cost(90 days)
- Measurement of quality of life(5 years)
- Revenues(90 days)
- Cost-effectiveness(90 days)
- Cost-utility analysis(90 days)